Related Experiment Video
Updated: Mar 29, 2026
10:46
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
Published on: May 26, 2015
13.9K
Decrease in B-Type Natriuretic Peptide Levels and Successful Catheter Ablation for Atrial Fibrillation in Patients
Satoshi Yanagisawa1, Yasuya Inden1, Hiroyuki Kato1
1Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Pacing and Clinical Electrophysiology : PACE
|November 25, 2015
Summary
Successful catheter ablation significantly reduced B-type natriuretic peptide (BNP) levels in heart failure patients with atrial fibrillation (AF). This reduction in BNP correlates with improved cardiac function and sustained sinus rhythm.
Area of Science:
- Cardiology
- Electrophysiology
- Heart Failure Management
Background:
- Limited data exists on B-type natriuretic peptide (BNP) levels following catheter ablation for atrial fibrillation (AF) in heart failure patients.
- Association between AF elimination and BNP levels in patients with left ventricular systolic dysfunction is not well understood.
Purpose of the Study:
- To investigate the impact of catheter ablation for AF on BNP levels.
- To assess the relationship between successful AF ablation and changes in BNP in patients with impaired left ventricular ejection fraction (LVEF).
Main Methods:
- Radiofrequency catheter ablation for AF was performed in 54 patients with LVEF ≤ 50%.
- BNP levels were measured at baseline, 3 days, and 1 month post-ablation.
- Patients were followed for 6 months to assess AF recurrence.
Main Results:
- BNP levels significantly decreased in patients without AF recurrence (P < 0.001) but not in those with recurrence (P = 0.368).
- A greater percentage reduction in BNP from baseline to 1 month was observed in the non-recurrence group (56.5%) compared to the recurrence group (-2.4%, P = 0.027).
- BNP reduction correlated with LVEF improvement (r = 0.486, P < 0.001).
Conclusions:
- Successful catheter ablation of AF leads to significant reductions in plasma BNP levels in patients with impaired LVEF.
- Decreased BNP levels may indicate early cardiac function recovery and successful maintenance of sinus rhythm.
Keywords:
B-type natriuretic peptideatrial fibrillationcatheter ablationheart failurereverse remodelingMore Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
11.1K
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
34.3K
Related Concept Videos
01:29Heart Failure II: Pathophysiology
1.4K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:22Heart Failure Drugs: β-Blockers
1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
01:30Heart Failure V: Medical Management
520
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
520
01:22Heart Failure VI: Adjunct Therapies
557
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
557
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K